A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Public ClinicalTrials.gov record NCT06500884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Randomized Study to Evaluate GPRC5D-related Oral Events
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.
Study identification
- NCT ID
- NCT06500884
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Interventions
- Talquetamab Drug
- Prophylaxis A Drug
- Prophylaxis B Drug
- Prophylaxis C Drug
- Prophylaxis D Drug
- Ramantamig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2024
- Primary completion
- May 29, 2030
- Completion
- May 29, 2030
- Last update posted
- Aug 27, 2026
2024 – 2030
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94143 | Recruiting |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | Recruiting |
| Yale University School Of Medicine | New Haven | Connecticut | 06510 | Recruiting |
| Icahn School of Medicine at Mt. Sinai | New York | New York | 10029 | Recruiting |
| University of Rochester Medical Center | Rochester | New York | 14642 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27705 | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| Virginia Commonwealth University - Massey Cancer Center | Richmond | Virginia | 23298 | Recruiting |
| University of Washington | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06500884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06500884 live on ClinicalTrials.gov.